By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    medicare part d benefits
    Everything that You Need to Know About Medicare Part D
    August 15, 2022
    Best Ways to Boost Your Immune System this Winter
    Best Ways to Boost Your Immune System this Winter
    November 15, 2022
    back pain issues
    Ways to Treat Constant Back Pain
    August 21, 2023
    Latest News
    How Probate Planning Shapes the Future of Your Estate and Family Care
    July 17, 2025
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    More On Wellness Programs To Improve Health and Reduce Costs
    January 25, 2012
    Privatizing Social Security and Medicare: Who Can Defuse Political Dynamite?
    June 12, 2011
    Study: Risk of Death in Elderly Patients with Dementia Doubled with Some Antipsychotic Medications
    February 26, 2012
    Latest News
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
    How Health Choices and Legal Actions Intersect After an Injury
    July 17, 2025
    How communities and healthcare providers can address slip and fall injuries with legal awareness
    July 17, 2025
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Pharma: Funding R&D: High Prices, Overuse A Failed Strategy
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Pharma: Funding R&D: High Prices, Overuse A Failed Strategy
BusinessNewsSpecialties

Pharma: Funding R&D: High Prices, Overuse A Failed Strategy

gooznews
gooznews
Share
7 Min Read
SHARE

Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer’s Lipitor lose patent protection. Biotech generic competition is on the horizon.

Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer’s Lipitor lose patent protection. Biotech generic competition is on the horizon.

The industry’s sleazier marketing techniques are in decline. Physicians are turning their backs on fancy dinners and sham consulting contracts, and not just because the companies were forced to fork over billions of dollars to settle government anti-kickback suits. Starting in 2013, patients of every physician who takes money from a drug or medical device company will be able to find that fact and the amount in a publicly available internet database, courtesy of the Affordable Care Act, a.k.a. Obamacare.

Meanwhile, the udders on the cash cows that for decades made the industry the most profitable in America are running dry. The insurers who manage Medicare and Medicaid’s drug plans are watching every penny. They are forcing generic substitution wherever possible and will soon have a growing body of comparative effectiveness research to fend off charges they are rationing drugs when they turn down payment for expensive new products that are no better than the ones that are already on the market.

More Read

How To Manage Mental Health As An Entrepreneur
Changing Behavior to Conquer Obesity
How to Improve Sex Life – Recommendations for Couples
Big Data: What It Means for Science, Healthcare and Social Media
23: Number of Useful Internet Marketing Stats in This Healthcare Post

Over in the firms’ R&D departments, the pipeline for blockbuster products – defined as drugs that generate over a billion dollars a year – is running dry. To justify their huge research infrastructures, companies are now charging $100,000 a year and more for new drugs, which often deliver only a marginal improvement in health, especially in cancer treatments.  Industry officials publicly fret about where they are going to find revenue to develop the next generation of cures.

Last week’s news from the frontiers of medical science highlighted the problems facing an industry tripping over its existing business model, which funds R&D by getting more and more people to use its older yet still on-patent drugs.

On Thursday a Food and Drug Administration advisory committee gave its blessing to a Gilead Science pill that can prevent AIDS transmission. Truvada, a combination of two drugs used to treat people with AIDS, reduces transmission by 63 percent if taken routinely by an uninfected partner. If the FDA agrees with the committee, and it usually does, it will be the first time the agency has approved a drug that prevents person-to-person transmission of the human immunodeficiency virus that causes AIDS.

At first blush, it might appear that there’s a large market for such a pill. There are an estimated one million people in the U.S. living with HIV/AIDS. There are about 50,000 new infections each year. Since unprotected sex between an infected and uninfected partner remains the largest single cause of transmission, it might seem like there is a large market for the $11,000-a-year drug.

But as Scott Hensley at NPR’s Shots blog pointed out, doctors are not rushing to prescribe the pill for partners of their infected patients fearing they won’t stick to the daily regimen yet avoid other forms of protection (condom use). There are also nasty side effects with the drugs as there are with all AIDS medications. Gilead CEO John Martin told reporters in January he didn’t see a significant commercial opportunity from the new designation.

On Friday, the New York Times reported a new study of patients on dialysis that showed that the government’s bundled payment scheme to reduce use of an expensive anti-anemia drug – Amgen’s Epogen – had led to a small increase in blood transfusions. Dialysis clinics have dialed back their use of the drug to save money. The number of monthly transfusions grew 9 to 22 percent last year to about 10,000 a month (up from about 8,250) among the nation’s 400,000 dialysis patients.

But many renal physicians will find that an acceptable trade-off, since overuse of the drug leads to increased heart attacks and strokes among the vulnerable population on dialysis. “It might be seen as an acceptable trade-off to exchange a higher risk of cardiovascular attack for a higher risk of transfusion,” the paper noted.

In a third example where less equals more, Food and Drug Administration scientists reported in last week’s New England Journal of Medicine that widely-used bisphosphonates for preventing bone deterioration in post-menopausal women did not help women after about three years on the drugs and should probably only be used on women who are at serious risk of fractures. The drugs, which on rare occasions trigger spontaneous bone breaks and necrosis of the jaw, are often prescribed  to women whose only bone problems show up on bone-density scans.

What do all these situations have in common? Companies that developed useful therapies for particular conditions went looking for ways to get their products used by much wider populations in order to generate higher profits and money to invest in R&D. But since the benefits to those larger, less sick populations were far smaller than what had been seen in the original group for which the drugs were intended, the risks eventually outweighed the benefits.

That’s not an effective way for an industry – or a nation – to fund medical research. Industry scientists need to focus on unsolved problems like dementia or cancer, not on research that seeks to justify peddling pills to people who don’t really need them.

TAGGED:pharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
How IT and Marketing Teams Can Collaborate to Protect Patient Trust
Global Healthcare Policy & Law
July 17, 2025
paramedics in surgical gloves and masks
How Health Choices and Legal Actions Intersect After an Injury
Health care
July 16, 2025
a woman giving a key
How Probate Planning Shapes the Future of Your Estate and Family Care
Health
July 16, 2025
a woman with kinesio tapes on her back arm
How communities and healthcare providers can address slip and fall injuries with legal awareness
Health care
July 16, 2025

You Might also Like

Palliative Care Teams – A Big Improvement in Quality of Life

February 21, 2011

Patient Activation and the End of Health Insurance Companies

April 6, 2014
pharmphorum Facebook and healthcare
BusinessMobile HealthSocial Media

Is Facebook the Next Big Thing in Healthcare?

October 8, 2014
BusinessSocial Media

3 Reasons For Healthcare Professionals To Use Social Media

April 2, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?